Aesica is investing $4.7 million in a new high containment facility, significantly extending its current capabilities in the formulation and packaging of liquid and solid dosage forms. The facility will be completed by May 2011 and will enable the company to manufacture potent drugs typically classed as Safebridge category 3. The new facility will also include security measures that will ensure it can manufacture Schedule II controlled drugs such as opiates. The new high containment unit will...